Akili, Inc. (AKLI)
Market Cap | 34.01M |
Revenue (ttm) | 1.95M |
Net Income (ttm) | -48.55M |
Shares Out | 78.73M |
EPS (ttm) | -0.61 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 236,452 |
Open | 0.430 |
Previous Close | 0.435 |
Day's Range | 0.430 - 0.449 |
52-Week Range | 0.191 - 1.250 |
Beta | 1.72 |
Analysts | Buy |
Price Target | 4.00 (+825.93%) |
Earnings Date | Aug 8, 2024 |
About AKLI
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attent... [Read more]
Financial Performance
In 2023, Akili's revenue was $1.68 million, an increase of 419.50% compared to the previous year's $323,000. Losses were -$59.49 million, 212.5% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AKLI stock is "Buy" and the 12-month stock price forecast is $4.0.
News
![](https://cdn.snapi.dev/images/v1/c/t/press16-2506391.jpg)
Virtual Therapeutics Announces Results of Tender Offer to Acquire Akili Interactive
KIRKLAND, Wash. & BOSTON--(BUSINESS WIRE)--Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games (“Virtual Therapeutics”), today announced that it...
![](https://cdn.snapi.dev/images/v1/h/n/press20-2485550.jpg)
Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-...
![](https://cdn.snapi.dev/images/v1/v/q/press9-2480494.jpg)
AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI
NEW ORLEANS , June 14, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
![](https://cdn.snapi.dev/images/v1/e/j/press3-2468648.jpg)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT, SGE on Behalf of Shareholders
NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...
![](https://cdn.snapi.dev/images/v1/h/z/press12-2466894.jpg)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breach...
![](https://cdn.snapi.dev/images/v1/5/i/press3-2466706.jpg)
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger and Expiring Tender Offer - AKLI and CALT
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securi...
![](https://cdn.snapi.dev/images/v1/r/6/press17-2466602.jpg)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, SGE on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breach...
![](https://cdn.snapi.dev/images/v1/l/k/press18-2464998.jpg)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, WIRE on Behalf of Shareholders
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...
![](https://cdn.snapi.dev/images/v1/q/f/press15-2464706.jpg)
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. – AKLI
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Secur...
![](https://cdn.snapi.dev/images/v1/6/t/press11-2462754.jpg)
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLI
NEW YORK , June 4, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securitie...
![](https://cdn.snapi.dev/images/v1/i/h/press14-2459848.jpg)
AKLI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akili, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akili, Inc. (NASDAQ: AKLI) to Virtual Therapeutics for $0.4340 per share of common stock ...
![](https://cdn.snapi.dev/images/v1/a/n/press2-2452101.jpg)
Shareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE , May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Akili (Nasdaq: AKLI) for possible breaches of fiduciary duty and other violations of law in its transaction with Virtual Therapeutic...
![](https://cdn.snapi.dev/images/v1/w/7/press3-2451456.jpg)
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Interactive and Virtual Therapeutics Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company.
![](https://cdn.snapi.dev/images/v1/r/b/press2-2451392.jpg)
Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company
KIRKLAND, Wash. & BOSTON--(BUSINESS WIRE)--Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games, and Akili, Inc. (Nasdaq: AKLI), a leading digita...
![](https://cdn.snapi.dev/images/v1/b/i/press7-2430626.jpg)
Akili Reports First Quarter 2024 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2024 and provided an update on business pr...
![](https://cdn.snapi.dev/images/v1/c/4/press2-2399555.jpg)
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today provided several corporate updates, including an amendment to its strategic distribution agreement with S...
![](https://cdn.snapi.dev/images/v1/k/u/press11-2302274.jpg)
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2023, and provided an upd...
![](https://cdn.snapi.dev/images/v1/a/c/press3-2295020.jpg)
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastat...
![](https://cdn.snapi.dev/images/v1/q/u/press16-2293432.jpg)
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in Japan
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili's digital therapeutic SDT-001 ...
![](https://cdn.snapi.dev/images/v1/e/e/conf9-2287046.jpg)
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today provided several corporate updates, including that it plans to report fourth quarter and full year 2023 f...
![](https://cdn.snapi.dev/images/v1/t/l/press1-2151023.jpg)
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update
BOSTON--(BUSINESS WIRE)--Akili Reports Third Quarter 2023 Financial Results and Provides Business Update.
![](https://cdn.snapi.dev/images/v1/k/q/conf15-2111817.jpg)
Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET
BOSTON--(BUSINESS WIRE)--Akili to Host Third Quarter Financial Results Conference Call on Thursday, November 9 at 4:30 p.m.
![](https://cdn.snapi.dev/images/v1/i/w/press1-2100522.jpg)
Employees with ADHD Aren't Reaching Their Full Potential at Work, Akili Study Finds
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), the leading digital medicine company behind EndeavorOTC™, today released results from a new study examining the ways in which ADHD impacts the U.S....
![](https://cdn.snapi.dev/images/v1/r/2/press17-2092855.jpg)
Akili Announces Leadership Transition
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appoint...
![](https://cdn.snapi.dev/images/v1/c/e/press6-2072554.jpg)
Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD
BOSTON--(BUSINESS WIRE)--Akili Releases EndeavorOTC on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD.